Stock Analysis on Net
Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

$19.99

Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Paying users area

Try for free

Bristol-Myers Squibb Co. pages available for free this week:

The data is hidden behind: . Unhide it.

  • Get 1-month access to Bristol-Myers Squibb Co. for $19.99, or

  • get full access to the entire website for at least 3 months from $49.99.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Bristol-Myers Squibb Co., consolidated balance sheet: liabilities and stockholders’ equity

US$ in millions

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
Short-term debt obligations
Accounts payable
Rebates and returns
Income taxes payable
Employee compensation and benefits
Research and development
Dividends
Interest
Royalties
Current operating lease liabilities
Contingent value rights
Other
Other current liabilities
Current liabilities
Deferred income taxes
Long-term debt, excluding current portion
Income taxes payable
Contingent value rights
Pension and postretirement
Non-current operating lease liabilities
Deferred income
Deferred compensation
Other
Other non-current liabilities
Non-current liabilities
Total liabilities
Preferred stock, $2 convertible series, par value $1 per share
Common stock, par value of $0.10 per share
Capital in excess of par value of stock
Accumulated other comprehensive loss
Retained earnings
Cost of treasury stock
Total Bristol-Myers Squibb Company shareholders’ equity
Noncontrolling interest
Total equity
Total liabilities and equity

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Bristol-Myers Squibb Co. current liabilities increased from 2018 to 2019 and from 2019 to 2020.
Non-current liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Bristol-Myers Squibb Co. non-current liabilities increased from 2018 to 2019 and from 2019 to 2020.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Bristol-Myers Squibb Co. total liabilities increased from 2018 to 2019 and from 2019 to 2020.
Total Bristol-Myers Squibb Company shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Bristol-Myers Squibb Co. total Bristol-Myers Squibb Company shareholders’ equity increased from 2018 to 2019 but then slightly decreased from 2019 to 2020.